Screener
Pacira BioSciences, Inc. PCRX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:07 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028871
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accounts payable | (936) | 2,464 |
| Accrued expenses | (10,305) | 4,702 |
| Other liabilities | 3,288 | 1,082 |
| Net cash provided by operating activities | 25,680 | 35,459 |
| Investing activities: | ||
| Acquisition of GQ Bio Therapeutics GmbH (net of cash acquired) | (335) | (16,702) |
| Purchases of fixed assets | (2,724) | (8,548) |
| Purchases of available-for-sale investments | — | (69,629) |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Pacira BioSciences, Inc.'s operating cash flow?
- Pacira BioSciences, Inc. (PCRX) reported operating cash flow of $25.68M in Q1 2026.
- How has Pacira BioSciences, Inc.'s operating cash flow changed year-over-year?
- Pacira BioSciences, Inc.'s operating cash flow decreased by 27.6% year-over-year, from $35.46M to $25.68M.
- What is the long-term trend for Pacira BioSciences, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Pacira BioSciences, Inc.'s operating cash flow has grown at a 4.9% compound annual growth rate (CAGR), from $125.72M to $151.99M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Pacira BioSciences, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude